1. The role of ultra-rapid-acting insulin analogs in diabetes : an expert consensusFrancesco Giorgino, Tadej Battelino, Richard Bergenstal, Thomas Forst, Jennifer B. Green, Chantal Mathieu, Helena W. Rodbard, Oliver Schnell, Emma G. Wilmot, 2025, pregledni znanstveni članek Povzetek: Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-acting insulin analogs. Because of their adapted formulation, URAA provide an even faster pharmacokinetics and thus an accelerated onset of insulin action than conventional rapid-acting insulin analogs, allowing for a more physiologic delivery of exogenously applied insulin. Clinical trials have confirmed the superiority of URAA in controlling postprandial glucose excursions, with a safety profile that is comparable to the rapid-acting insulins. Consequently, many individuals with diabetes mellitus may benefit from URAA in terms of prandial glycemic control. Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context
Ključne besede: ultra-rapid-acting insulin, URLi, faster aspart, insulin therapy, type I diabetes, type 2 diabetes
Objavljeno v DiRROS: 22.04.2026; Ogledov: 359; Prenosov: 349
 Celotno besedilo (166,87 KB)
Gradivo ima več datotek! Več... |
2. CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetesThomas Martens, Tadej Battelino, Simon Heller, Anuj Bhargava, Linong Ji, Sreenivasa Murthy, 2026, izvirni znanstveni članek Ključne besede: basal insulin, continuous glucose monitoring, CGM, insulin therapy, type 2 diabetes
Objavljeno v DiRROS: 23.03.2026; Ogledov: 363; Prenosov: 1469
Celotno besedilo (673,92 KB)
Gradivo ima več datotek! Več... |
3. Residual metabolic burden in young psoriasis patients successfully treated with biologicsEva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Miodrag Janić, 2024, izvirni znanstveni članek Povzetek: Metabolic disorders are common in patients with psoriasis and contribute significantly to an increased cardiovascular risk. While biologic therapy is very successful in clearing skin lesions, its impact on metabolic parameters is uncertain. Our aim was to investigate the residual metabolic burden in psoriasis patients successfully treated with biologic therapy. We conducted a cross-sectional study of 80 young patients (54 men, 26 women, aged 30–45 years) successfully treated with either adalimumab, secukinumab or guselkumab and topical therapy or methotrexate, and 20 healthy controls. Anthropometric parameters, lipid levels and metabolic indices (HOMA-IR, TyG index and FIB-4 index) were measured. Patients did not receive any other treatments to exclude confounding effects. After analysis, we found that patients treated with three different biologics had similar metabolic status, only the FIB-4 index was higher in the adalimumab group than in the secukinumab and guselkumab treatment groups. There were no significant differences between the patients treated with biologics and the control group. The comparison with patients treated topically or with methotrexate showed that only triglyceride levels, HOMA-IR, TyG index, and FIB-4 index were elevated in patients treated with adalimumab compared to patients treated with topical therapy. Finally, metabolic status was also similar in patients treated with methotrexate or topical therapy. In conclusion, this study suggests that psoriasis patients successfully treated with biologics have similar metabolic parameters to the control group and patients treated with topical therapy or methotrexate. This indicates that there is no significant residual metabolic burden in young patients successfully treated with biologics. These results are clinically relevant and should be considered in the treatment of psoriasis patients.
Ključne besede: psoriasis, residual metabolic burden, insulin resistance, biologic therapy
Objavljeno v DiRROS: 09.12.2025; Ogledov: 542; Prenosov: 380
Celotno besedilo (1,39 MB)
Gradivo ima več datotek! Več... |
4. Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetesKlemen Dovč, Kevin Cargnelutti, Anže Šturm, Julij Šelb, Nataša Bratina, Tadej Battelino, 2018, izvirni znanstveni članek Povzetek: Aims. The objective of this nationwide population-based cohort study was to evaluate the correlation between continuous glucose monitoring (CGM) use and glucose variability in pre-schoolers with type 1 diabetes.
Methods. We analysed data from the Slovenian National Registry. The primary endpoint was the difference in glucose variability between periods, during which participants were using CGM and periods, during which CGM was not used, over 5 years. Results. A total of 40 children <8 years old were followed for an estimated observational period of 116 patient/years. Mean age at CGM initiation was 3.5 (±1.7) years. Both standard deviation of mean glucose [3.6 mmol/L (3.2–3.9) with CGM and 4.3 mmol/L (3.8–4.7) without CGM, p < 0.001] and coefficient of variation [44.0% (40.4–47.0) with CGM and 46.1% (42.3–49.4) without CGM, p = 0.021] were lower during the periods, when CGM was used. Frequent CGM use (>5 days/week) was associated with a 0.4% [4.4 mmol/mol] reduction in glycated haemoglobin level (7.6% compared to 7.2%, p = 0.047). Conclusions. Our results indicate that the use of CGM was associated with reduced glucose variability during a 5 year follow-up period among pre-schoolers with type 1 diabetes.
Ključne besede: continuous glucose monitoring, type 1 diabetes, children, insulin therapy
Objavljeno v DiRROS: 12.11.2020; Ogledov: 3033; Prenosov: 1786
Celotno besedilo (738,73 KB)
Gradivo ima več datotek! Več... |
